Q4 2021 Results
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
Financial performance
Innovation: Pipeline overview
Innovation: Clinical trials
Neuroscience
Ophthalmology
Respiratory & Allergy
Oncology: Solid Tumors
Hematology
Biosimilars
Global Health
Abbreviations
CRM
IHD
AdakveoⓇ
-
P-selectin inhibitor
Study
Indication
Phase
Patients
Primary Outcome
Measures
Arms Intervention
NCT03814746 STAND (CSEG101A2301)
Prevention of Vaso-Occlusive Crises (VOC) in patients with Sickle Cell Disease
(SCD)
Phase 3
240
Rate of VOC events leading to healthcare visit
Crizanlizumab 5.0 mg/kg
Crizanlizumab 7.5 mg/kg
Placebo
Adolescent and adult SCD patients (12 years and older)
Target Patients
Read-out Milestone(s)
2022
Publication
TBD
127 Investor Relations | Q4 2021 Results
NOVARTIS | Reimagining MedicineView entire presentation